The AACR Journals: Advancing Progress Toward the AACR’s 115-Year Mission

Kenneth C. Anderson; Lewis C. Cantley; Riccardo Dalla-Favera; Chi Van Dang; Luis A. Diaz; Raymond N. DuBois; Keith T. Flaherty; Philip D. Greenberg; Massimo Loda; Elaine R. Mardis; Elizabeth A. Platz; Michael N. Pollak; Robert D. Schreiber; Lillian L. Siu; Beverly A. Teicher

doi:10.1158/1078-0432.CCR-22-3167

The AACR Journals: Advancing Progress Toward the AACR’s 115-Year Mission

Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A. Diaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michael N. Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	4593-4599
Number of pages	7
Journal	Clinical Cancer Research
Volume	28
Issue number	21
DOIs	https://doi.org/10.1158/1078-0432.CCR-22-3167
State	Published - Nov 1 2022

Access to Document

10.1158/1078-0432.CCR-22-3167

Cite this

Anderson, K. C., Cantley, L. C., Dalla-Favera, R., Van Dang, C., Diaz, L. A., DuBois, R. N., Flaherty, K. T., Greenberg, P. D., Loda, M., Mardis, E. R., Platz, E. A., Pollak, M. N., Schreiber, R. D., Siu, L. L., & Teicher, B. A. (2022). The AACR Journals: Advancing Progress Toward the AACR’s 115-Year Mission. Clinical Cancer Research, 28(21), 4593-4599. https://doi.org/10.1158/1078-0432.CCR-22-3167

@article{db0a3bae7da046ea9c3381aafc82cd18,

title = "The AACR Journals: Advancing Progress Toward the AACR{\textquoteright}s 115-Year Mission",

author = "Anderson, {Kenneth C.} and Cantley, {Lewis C.} and Riccardo Dalla-Favera and {Van Dang}, Chi and Diaz, {Luis A.} and DuBois, {Raymond N.} and Flaherty, {Keith T.} and Greenberg, {Philip D.} and Massimo Loda and Mardis, {Elaine R.} and Platz, {Elizabeth A.} and Pollak, {Michael N.} and Schreiber, {Robert D.} and Siu, {Lillian L.} and Teicher, {Beverly A.}",

note = "Funding Information: L. Cantley consulted for Petra Pharmaceuticals, Agios Pharmaceuticals, EIP Pharmaceuticals, Volastra, Larkspur, and Cell Signaling Technologies over the past year. He also received grant support from the NIH/NCI, Gray Foundation, The Mark Foundation, the Breast Cancer Research Foundation, and Stand Up To Cancer/ American Association for Cancer Research over the past year, and is a stockholder in Agios Pharmaceuticals, EIP Pharmaceuticals, Cell Signaling Technologies, Volastra, and Larkspur. R. Dalla-Favera is a consultant for NeoGenomics and AstraZeneca and receives research funds from AstraZeneca. L.A. Diaz is a member of the board of directors of Jounce Therapeutics and Epitope and is a compensated consultant to PetDx, Innovatus CP, Se{\textquoteright}er, Delfi, Blackstone, Kinnate, and Neophore. He is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy; some of these licenses and relationships are associated with equity or royalty payments directly to the inventors. He holds equity in Epitope, Jounce Therapeutics, PetDx, Se{\textquoteright}er, Delfi, Kinnate, and Neophore; he divested his equity in Personal Genome Diagnostics to LabCorp in February 2022 and he divested his equity in Thrive Earlier Detection to Exact Biosciences in January 2021. His spouse holds equity in Amgen. The terms of all these arrangements are being managed by Memorial Sloan Kettering in accordance with their conflict of interest policies. K.T. Flaherty reports personal fees from Clovis Oncology, Checkmate Pharmaceuticals, Strata Oncology, Kinnate Biopharma, Scorpion Therapeutics, PIC Therapeutics, Apricity, Tvardi, ALX Oncology, xCures,",

year = "2022",

month = nov,

day = "1",

doi = "10.1158/1078-0432.CCR-22-3167",

language = "English",

volume = "28",

pages = "4593--4599",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "21",

}

Anderson, KC, Cantley, LC, Dalla-Favera, R, Van Dang, C, Diaz, LA, DuBois, RN, Flaherty, KT, Greenberg, PD, Loda, M, Mardis, ER, Platz, EA, Pollak, MN, Schreiber, RD, Siu, LL & Teicher, BA 2022, 'The AACR Journals: Advancing Progress Toward the AACR’s 115-Year Mission', Clinical Cancer Research, vol. 28, no. 21, pp. 4593-4599. https://doi.org/10.1158/1078-0432.CCR-22-3167

TY - JOUR

T1 - The AACR Journals

T2 - Advancing Progress Toward the AACR’s 115-Year Mission

AU - Anderson, Kenneth C.

AU - Cantley, Lewis C.

AU - Dalla-Favera, Riccardo

AU - Van Dang, Chi

AU - Diaz, Luis A.

AU - DuBois, Raymond N.

AU - Flaherty, Keith T.

AU - Greenberg, Philip D.

AU - Loda, Massimo

AU - Mardis, Elaine R.

AU - Platz, Elizabeth A.

AU - Pollak, Michael N.

AU - Schreiber, Robert D.

AU - Siu, Lillian L.

AU - Teicher, Beverly A.

N1 - Funding Information: L. Cantley consulted for Petra Pharmaceuticals, Agios Pharmaceuticals, EIP Pharmaceuticals, Volastra, Larkspur, and Cell Signaling Technologies over the past year. He also received grant support from the NIH/NCI, Gray Foundation, The Mark Foundation, the Breast Cancer Research Foundation, and Stand Up To Cancer/ American Association for Cancer Research over the past year, and is a stockholder in Agios Pharmaceuticals, EIP Pharmaceuticals, Cell Signaling Technologies, Volastra, and Larkspur. R. Dalla-Favera is a consultant for NeoGenomics and AstraZeneca and receives research funds from AstraZeneca. L.A. Diaz is a member of the board of directors of Jounce Therapeutics and Epitope and is a compensated consultant to PetDx, Innovatus CP, Se’er, Delfi, Blackstone, Kinnate, and Neophore. He is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy; some of these licenses and relationships are associated with equity or royalty payments directly to the inventors. He holds equity in Epitope, Jounce Therapeutics, PetDx, Se’er, Delfi, Kinnate, and Neophore; he divested his equity in Personal Genome Diagnostics to LabCorp in February 2022 and he divested his equity in Thrive Earlier Detection to Exact Biosciences in January 2021. His spouse holds equity in Amgen. The terms of all these arrangements are being managed by Memorial Sloan Kettering in accordance with their conflict of interest policies. K.T. Flaherty reports personal fees from Clovis Oncology, Checkmate Pharmaceuticals, Strata Oncology, Kinnate Biopharma, Scorpion Therapeutics, PIC Therapeutics, Apricity, Tvardi, ALX Oncology, xCures,

PY - 2022/11/1

Y1 - 2022/11/1

UR - http://www.scopus.com/inward/record.url?scp=85140942559&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-22-3167

DO - 10.1158/1078-0432.CCR-22-3167

M3 - Editorial

C2 - 36317374

AN - SCOPUS:85140942559

SN - 1078-0432

VL - 28

SP - 4593

EP - 4599

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 21

ER -

The AACR Journals: Advancing Progress Toward the AACR’s 115-Year Mission

Access to Document

Other files and links

Cite this